Shi Si Ban Shuang Cheng Pharmaceutical: The company is planning a major asset restructuring, and the specific transaction price has not been determined yet.

Jinshi Data News on October 9th, Shuangcheng Pharmaceutical announced that the company is planning a major asset restructuring, and the audit and evaluation of this transaction have not been completed, and the specific transaction price has not yet been determined. This transaction still needs to be reviewed by the company’s board of directors and approved by the company’s shareholders’ meeting, and can only be officially implemented after approval by relevant regulatory authorities. There is still some uncertainty as to whether it can be approved. The company achieved operating income of 94.8926 million yuan in the first half of 2024, a year-on-year decrease of 31.74%, and a net loss of 16.9462 million yuan. Recently, the company’s stock trading price has fluctuated significantly. Investors are requested to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.